Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes
Purpose. To evaluate the efficacy of dexamethasone implant (DEX) for the treatment of postoperative cystoid macular edema (PCME) in vitrectomized eyes and to investigate visual and morphological OCT predictive factors. Methods. In this retrospective study, eyes with PCME after vitrectomy were treate...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/3946531 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568557747044352 |
|---|---|
| author | Sigrid Freissinger Efstathios Vounotrypidis Armin Wolf Karsten U. Kortuem Mehdi Shajari Filippos Sakkias Tina Herold Siegfried G. Priglinger Wolfgang J. Mayer |
| author_facet | Sigrid Freissinger Efstathios Vounotrypidis Armin Wolf Karsten U. Kortuem Mehdi Shajari Filippos Sakkias Tina Herold Siegfried G. Priglinger Wolfgang J. Mayer |
| author_sort | Sigrid Freissinger |
| collection | DOAJ |
| description | Purpose. To evaluate the efficacy of dexamethasone implant (DEX) for the treatment of postoperative cystoid macular edema (PCME) in vitrectomized eyes and to investigate visual and morphological OCT predictive factors. Methods. In this retrospective study, eyes with PCME after vitrectomy were treated with at least one DEX injection and were observed over 12 months. Indications for surgery were epiretinal membrane (ERM) or rhegmatogenous retinal detachment (RRD) without macular involvement. Prior treatments, if any, were noted. Best corrected visual acuity (BCVA), central foveal thickness (CFT), and OCT morphology including the presence of intraretinal cysts/fluid or subretinal fluid (IRF/SRF) and ellipsoid zone (EZ) continuity were evaluated. Correlations between OCT measures and visual outcomes were analyzed by the generalized estimating equations procedure. Results. Forty-six eyes with ERM and 15 eyes with RRD were enrolled. The ERM group was more likely to gain BCVA than RRD (odds ratio (OR), 1.168; 95% confidence interval (CI), 1.003–1.360; p=0.046). The absence of SRF (OR, 0.860; 95% CI, 0.743–0.995; p=0.043) was predictive of worse BCVA, whereas the integrity of EZ (OR, 1.094; 95% CI, 0.951–1.257; p=0.209) or naïve status (OR, 0.946; 95% CI, 0.871–1.137, p=0.853) was not. Eyes with a worse baseline BCVA were more likely to gain >1 line after 12 months (OR, 1.485; 95% CI, 1.171–1.884; p=0.001). Conclusion. The efficacy of the treatment of PCME in vitrectomized eyes seems to be affected by baseline BCVA, the absence of SRF, and the indication for surgery. Naïve status appears not to play any significant role in the prediction of BCVA. This trial is registered with DRKS00018955. |
| format | Article |
| id | doaj-art-32fc362259084e51b14ff0f7fa5debaf |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-32fc362259084e51b14ff0f7fa5debaf2025-02-03T00:58:45ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/39465313946531Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized EyesSigrid Freissinger0Efstathios Vounotrypidis1Armin Wolf2Karsten U. Kortuem3Mehdi Shajari4Filippos Sakkias5Tina Herold6Siegfried G. Priglinger7Wolfgang J. Mayer8Department of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyPurpose. To evaluate the efficacy of dexamethasone implant (DEX) for the treatment of postoperative cystoid macular edema (PCME) in vitrectomized eyes and to investigate visual and morphological OCT predictive factors. Methods. In this retrospective study, eyes with PCME after vitrectomy were treated with at least one DEX injection and were observed over 12 months. Indications for surgery were epiretinal membrane (ERM) or rhegmatogenous retinal detachment (RRD) without macular involvement. Prior treatments, if any, were noted. Best corrected visual acuity (BCVA), central foveal thickness (CFT), and OCT morphology including the presence of intraretinal cysts/fluid or subretinal fluid (IRF/SRF) and ellipsoid zone (EZ) continuity were evaluated. Correlations between OCT measures and visual outcomes were analyzed by the generalized estimating equations procedure. Results. Forty-six eyes with ERM and 15 eyes with RRD were enrolled. The ERM group was more likely to gain BCVA than RRD (odds ratio (OR), 1.168; 95% confidence interval (CI), 1.003–1.360; p=0.046). The absence of SRF (OR, 0.860; 95% CI, 0.743–0.995; p=0.043) was predictive of worse BCVA, whereas the integrity of EZ (OR, 1.094; 95% CI, 0.951–1.257; p=0.209) or naïve status (OR, 0.946; 95% CI, 0.871–1.137, p=0.853) was not. Eyes with a worse baseline BCVA were more likely to gain >1 line after 12 months (OR, 1.485; 95% CI, 1.171–1.884; p=0.001). Conclusion. The efficacy of the treatment of PCME in vitrectomized eyes seems to be affected by baseline BCVA, the absence of SRF, and the indication for surgery. Naïve status appears not to play any significant role in the prediction of BCVA. This trial is registered with DRKS00018955.http://dx.doi.org/10.1155/2020/3946531 |
| spellingShingle | Sigrid Freissinger Efstathios Vounotrypidis Armin Wolf Karsten U. Kortuem Mehdi Shajari Filippos Sakkias Tina Herold Siegfried G. Priglinger Wolfgang J. Mayer Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes Journal of Ophthalmology |
| title | Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes |
| title_full | Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes |
| title_fullStr | Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes |
| title_full_unstemmed | Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes |
| title_short | Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes |
| title_sort | evaluation of functional outcomes and oct biomarkers after intravitreal dexamethasone implant for postoperative cystoid macular edema in vitrectomized eyes |
| url | http://dx.doi.org/10.1155/2020/3946531 |
| work_keys_str_mv | AT sigridfreissinger evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT efstathiosvounotrypidis evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT arminwolf evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT karstenukortuem evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT mehdishajari evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT filippossakkias evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT tinaherold evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT siegfriedgpriglinger evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes AT wolfgangjmayer evaluationoffunctionaloutcomesandoctbiomarkersafterintravitrealdexamethasoneimplantforpostoperativecystoidmacularedemainvitrectomizedeyes |